Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 3Plasma cell 2Classical hematology 2Other hematologic neoplasm 1

Conditions

Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Leukemia, Monocytic, Acute 1Leukemia, Lymphoid 1Hodgkin Disease 1Hematologic Neoplasms 1

Interventions

Cyclophosphamide 131fludarabine phosphate 108Mycophenolic Acid 92Peripheral Blood Stem Cell Transplantation 91Whole-Body Irradiation 80Tacrolimus 78Busulfan 64Cyclosporine 60fludarabine 55Melphalan 55Filgrastim 54Antilymphocyte Serum 48Methotrexate 41Radiotherapy 39Etoposide 35Rituximab 33Granulocyte Colony-Stimulating Factor 27Sirolimus 25Cytarabine 23Stem Cell Transplantation 21Cord Blood Stem Cell Transplantation 21thymoglobulin 20Thiotepa 19Methylprednisolone 18sargramostim 17Cyclosporins 16Carmustine 16Alemtuzumab 16Therapeutics 13Psychiatric Rehabilitation 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hodgkin Disease × romiplostim × Other hematologic neoplasm × Clear all
NCT02046291 2021-06-08

Safety of Romiplostim (Nplate®) Following UCBT

Masonic Cancer Center, University of Minnesota

Phase 1 Completed
21 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Hodgkin Disease, Leukemia, Lymphoid, Leukemia, Monocytic, Acute, Lymphoma, Non-Hodgkin, Multiple Myeloma, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡